GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Gross-Profit-to-Asset %

Telix Pharmaceuticals (Telix Pharmaceuticals) Gross-Profit-to-Asset % : 95.83% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Telix Pharmaceuticals's annualized Gross Profit for the quarter that ended in Dec. 2023 was $227.5 Mil. Telix Pharmaceuticals's average Total Assets over the quarter that ended in Dec. 2023 was $237.4 Mil. Therefore, Telix Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 95.83%.


Telix Pharmaceuticals Gross-Profit-to-Asset % Historical Data

The historical data trend for Telix Pharmaceuticals's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Gross-Profit-to-Asset % Chart

Telix Pharmaceuticals Annual Data
Trend Sep99 Sep00 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only 1.03 2.11 1.70 50.80 94.10

Telix Pharmaceuticals Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.86 14.58 68.70 97.72 95.83

Competitive Comparison of Telix Pharmaceuticals's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Telix Pharmaceuticals's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telix Pharmaceuticals's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Telix Pharmaceuticals's Gross-Profit-to-Asset % falls into.



Telix Pharmaceuticals Gross-Profit-to-Asset % Calculation

Telix Pharmaceuticals's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=206.494/( (172.303+266.601)/ 2 )
=206.494/219.452
=94.10 %

Telix Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=227.536/( (208.279+266.601)/ 2 )
=227.536/237.44
=95.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Telix Pharmaceuticals Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Telix Pharmaceuticals (Telix Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.